Medicines for fatty liver disease and fibrosis have the potential to follow obesity’s extraordinary growth trajectory. The journey to a successful drug for severe fatty liver disease has been long and filled with setbacks, much like the search for effective obesity treatments. That changed in March 2024, when Madrigal’s Rezdiffra became the first FDA-approved therapy for fibrosis, with sales projected to hit $3 billion by 2030. As the obesity and diabetes epidemics continue to rise, metabolic dysfunction-associated steatohepatitis (MASH) is gaining more attention. By the end of the decade, the broader MASH therapy market could surpass $9.5 billion. Are we witnessing the next multi-billion dollar breakthrough in liver health?
Explore the possibilities in our latest eBook.
We ask:
- What’s coming down the MASH pipeline?
- Which Phase 3 or Phase 2 candidates are the most promising?
- Will multi-mechanism solutions prove most effective?
- Who are the private companies to watch?
